Cargando…
Macrocyclic Antimicrobial Peptides Engineered from ω-Conotoxin
The potent calcium channel blocker ω-conotoxin MVIIA is a linear cystine-knot peptide with multiple basic amino acids at both termini. This work shows that macrocyclization of MVIIA linking two positive-charge terminal clusters as a contiguous segment converts a conotoxin into an antimicrobial pepti...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470054/ https://www.ncbi.nlm.nih.gov/pubmed/28245769 http://dx.doi.org/10.2174/1381612822666161027120518 |
_version_ | 1783243699498516480 |
---|---|
author | Hemu, Xinya Tam, James P. |
author_facet | Hemu, Xinya Tam, James P. |
author_sort | Hemu, Xinya |
collection | PubMed |
description | The potent calcium channel blocker ω-conotoxin MVIIA is a linear cystine-knot peptide with multiple basic amino acids at both termini. This work shows that macrocyclization of MVIIA linking two positive-charge terminal clusters as a contiguous segment converts a conotoxin into an antimicrobial peptide. In addition, conversion of disulfide bonds to amino butyric acids improved the antimicrobial activity of the cyclic analogs. Ten macrocyclic analogs, with or without disulfide bonds, were prepared by both Boc and Fmoc chemistry using native chemical ligation. All cyclic analogs were active against selected Gram-positive and Gram-negative bacteria with minimal inhibitory concentrations in a low μM range. In contrast, MVIIA and its linear analog were inactive at concentrations up to 0.5 mM. The cyclic analogs also showed 2 to 3-fold improved chemotactic activity against human monocytes THP-1 compared with MVIIA. Reduction of molecular stability against thermal and acid treatment due to the reduced number of disulfide crosslinks can be partly restored by backbone cyclization. Together, these results show that macrocyclization and side chain modification of a linear conopeptide lead to a gain-of-function, which brings a new perspective in designing and engineering of peptidyl therapeutics. |
format | Online Article Text |
id | pubmed-5470054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-54700542017-06-28 Macrocyclic Antimicrobial Peptides Engineered from ω-Conotoxin Hemu, Xinya Tam, James P. Curr Pharm Des Article The potent calcium channel blocker ω-conotoxin MVIIA is a linear cystine-knot peptide with multiple basic amino acids at both termini. This work shows that macrocyclization of MVIIA linking two positive-charge terminal clusters as a contiguous segment converts a conotoxin into an antimicrobial peptide. In addition, conversion of disulfide bonds to amino butyric acids improved the antimicrobial activity of the cyclic analogs. Ten macrocyclic analogs, with or without disulfide bonds, were prepared by both Boc and Fmoc chemistry using native chemical ligation. All cyclic analogs were active against selected Gram-positive and Gram-negative bacteria with minimal inhibitory concentrations in a low μM range. In contrast, MVIIA and its linear analog were inactive at concentrations up to 0.5 mM. The cyclic analogs also showed 2 to 3-fold improved chemotactic activity against human monocytes THP-1 compared with MVIIA. Reduction of molecular stability against thermal and acid treatment due to the reduced number of disulfide crosslinks can be partly restored by backbone cyclization. Together, these results show that macrocyclization and side chain modification of a linear conopeptide lead to a gain-of-function, which brings a new perspective in designing and engineering of peptidyl therapeutics. Bentham Science Publishers 2017-05 2017-05 /pmc/articles/PMC5470054/ /pubmed/28245769 http://dx.doi.org/10.2174/1381612822666161027120518 Text en © 2017 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Hemu, Xinya Tam, James P. Macrocyclic Antimicrobial Peptides Engineered from ω-Conotoxin |
title | Macrocyclic Antimicrobial Peptides Engineered from ω-Conotoxin |
title_full | Macrocyclic Antimicrobial Peptides Engineered from ω-Conotoxin |
title_fullStr | Macrocyclic Antimicrobial Peptides Engineered from ω-Conotoxin |
title_full_unstemmed | Macrocyclic Antimicrobial Peptides Engineered from ω-Conotoxin |
title_short | Macrocyclic Antimicrobial Peptides Engineered from ω-Conotoxin |
title_sort | macrocyclic antimicrobial peptides engineered from ω-conotoxin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470054/ https://www.ncbi.nlm.nih.gov/pubmed/28245769 http://dx.doi.org/10.2174/1381612822666161027120518 |
work_keys_str_mv | AT hemuxinya macrocyclicantimicrobialpeptidesengineeredfromōconotoxin AT tamjamesp macrocyclicantimicrobialpeptidesengineeredfromōconotoxin |